RemeGen Biosciences
Qingwen Cheng holds the position of Sr. Scientist I at RemeGen Biosciences since April 2023, leading multiple antibody-drug conjugate projects aimed at developing monoclonal and bi-specific antibodies for cancer treatment. Prior to this role, Qingwen Cheng was a Scientist at Amgen from April 2004 to April 2023, where significant advancements in generating monocytes and macrophages from iPSC and differentiating hematopoietic stem cells were achieved. Earlier experience includes being an Associated Scientist at Tularik from April 1998 to March 2004, focusing on assays for G-protein coupled receptors and evaluating drug efficacy in diabetes and obesity models. Additionally, Qingwen Cheng served as a Research Associate at the University of California, Los Angeles from May 1998 to April 2001, contributing to research on chemotherapy-induced resistance and the immunogenicity of adenoviral vectors. Education was completed at Shanghai Second Medical University.
This person is not in any teams
RemeGen Biosciences
1 followers
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.